NASDAQ
VRNA

Verona Pharma PLC ADR

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Verona Pharma PLC ADR Stock Price

Vitals

Today's Low:
$19.155
Today's High:
$20.04
Open Price:
$19.36
52W Low:
$8.41
52W High:
$26.44
Prev. Close:
$19.41
Volume:
165212

Company Statistics

Market Cap.:
$1.54 billion
Book Value:
3.436
Revenue TTM:
$458000
Operating Margin TTM:
-12890.61%
Gross Profit TTM:
$112000
Profit Margin:
0%
Return on Assets TTM:
-16.09%
Return on Equity TTM:
-26.9%

Company Profile

Verona Pharma PLC ADR had its IPO on 2017-04-27 under the ticker symbol VRNA.

The company operates in the Healthcare sector and Biotechnology industry. Verona Pharma PLC ADR has a staff strength of 35 employees.

Stock update

Shares of Verona Pharma PLC ADR opened at $19.36 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $19.16 - $20.04, and closed at $19.87.

This is a +2.37% increase from the previous day's closing price.

A total volume of 165,212 shares were traded at the close of the day’s session.

In the last one week, shares of Verona Pharma PLC ADR have increased by +2.42%.

Verona Pharma PLC ADR's Key Ratios

Verona Pharma PLC ADR has a market cap of $1.54 billion, indicating a price to book ratio of 4.1364 and a price to sales ratio of 18.5606.

In the last 12-months Verona Pharma PLC ADR’s revenue was $458000 with a gross profit of $112000 and an EBITDA of $-58417000. The EBITDA ratio measures Verona Pharma PLC ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Verona Pharma PLC ADR’s operating margin was -12890.61% while its return on assets stood at -16.09% with a return of equity of -26.9%.

In Q2, Verona Pharma PLC ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Verona Pharma PLC ADR’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.65 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Verona Pharma PLC ADR’s profitability.

Verona Pharma PLC ADR stock is trading at a EV to sales ratio of 20.9648 and a EV to EBITDA ratio of -9.3954. Its price to sales ratio in the trailing 12-months stood at 18.5606.

Verona Pharma PLC ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$303.93 million
Total Liabilities
$10.95 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Verona Pharma PLC ADR ended 2024 with $303.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $303.93 million while shareholder equity stood at $273.09 million.

Verona Pharma PLC ADR ended 2024 with $0 in deferred long-term liabilities, $10.95 million in other current liabilities, 41753000.00 in common stock, $-359143000.00 in retained earnings and $545000.00 in goodwill. Its cash balance stood at $270.73 million and cash and short-term investments were $270.73 million. The company’s total short-term debt was $545,000 while long-term debt stood at $19.86 million.

Verona Pharma PLC ADR’s total current assets stands at $287.83 million while long-term investments were $15.00 million and short-term investments were $0. Its net receivables were $10.15 million compared to accounts payable of $2.49 million and inventory worth $894000.00.

In 2024, Verona Pharma PLC ADR's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Verona Pharma PLC ADR paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$19.87
52-Week High
$26.44
52-Week Low
$8.41
Analyst Target Price
$32.71

Verona Pharma PLC ADR stock is currently trading at $19.87 per share. It touched a 52-week high of $26.44 and a 52-week low of $26.44. Analysts tracking the stock have a 12-month average target price of $32.71.

Its 50-day moving average was $19.83 and 200-day moving average was $20.34 The short ratio stood at 11.89 indicating a short percent outstanding of 0%.

Around 301.1% of the company’s stock are held by insiders while 7889.5% are held by institutions.

Frequently Asked Questions About Verona Pharma PLC ADR

The stock symbol (also called stock or share ticker) of Verona Pharma PLC ADR is VRNA

The IPO of Verona Pharma PLC ADR took place on 2017-04-27

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1693.3
-79.35
-4.48%
$0.43
0.05
+12.04%
$211
-6.05
-2.79%
Neonode Inc (NEON)
$1.75
-0.02
-1.13%
$147.28
-1.43
-0.96%
$31.04
0.26
+0.84%
$0.54
-0.15
-21.45%
$7.2
0.12
+1.69%
$0.75
-0
-0.32%
$28.7
0.19
+0.67%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Address

3 More London Riverside, London, United Kingdom, SE1 2RE